Study demonstrates series of effects
Clasado and the Department of Psychiatry, University of Oxford, today announce the results of their latest pre-clinical study demonstrating a major role a prebiotic against neuro-inflammation and anxiety.
Published in the journal Brain, Behavior and Immunity, this is the first study to demonstrate that a prebiotic can have a modulatory role in neuro-immuno processes as well as reversing anxiety induced by inflammation.
The agent promoting acute inflammation (LPS) in mice induced, as expected, sickness behaviour with lower locomotor activity within the first 6 hours compared to the control group. Acute inflammation also induced anxiety 24 hours later, paralleled by significant increases in the brain, in pro-inflammatory cytokines and in a serotonin receptor. These receptors play a key role in the brain-gut axis, brain development and neuro-psychiatric disorders. The prebiotic reduced post-inflammation anxiety 24 hours post-LPS injection while the brain inflammation observed in the control group was normalised in the prebiotic group. The effects of the prebiotic were mediated by an action on the immune system and brain chemistry.
As an increasing number of brain disorders are related to alterations in the immune system, such as depression, schizophrenia or Alzheimer’s disease, this study contributes to the growing body of evidence that will open new perspectives in treating disorders relating to immune dysfunction, emotional distress, neuropsychiatric conditions, and cognitive decline.
Dr Phil Burnet, head researcher, University Department of Psychiatry, University of Oxford, said:
“This study has provided additional valuable insights into the complex interactions between the gut microbiota, brain, immune and central nervous systems. The results have provided the basis for more studies on Bimuno as a much-needed further research into a variety of conditions.”